Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Aug 15;6(8):e23522. doi: 10.1371/journal.pone.0023522

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

PMC Copyright notice

A-B: Phyisical map generated using Methylprimer Express software (v 1.0) is demonstrating the distribution of CpG islands (vertical red bars) and the position of the MSP primer pairs on the mouse Foxp3 (A) and Il-17 (B) promoter. PCR amplicons of promoter region of Foxp3 gene amplified by methylated or demethylated sets of primers in T cells activated in vitro with anti-CD3+anti-CD28 Abs, treated in the presence of VEH or TCDD, has also been depicted in the right panels. C-D: Real Time PCR demonstrating methylation/demethylation status of Foxp3 and IL-17 promoters in MLN and LPL in vivo. MLNs and LP lymphocytes were isolated from the four groups of mice as described in Fig 1. Data (mean ±SEM) from 3 independent experiments are shown. Comparisons were made between VEH vs DSS+VEH groups as well as between DSS+VEH vs DSS+TCDD groups. Asterisks (*) represent statistically significant (p<0.05) difference between VEH vs DSS+VEH treated groups, and between DSS+VEH vs DSS+TCDD treated groups.